Trulieve Cannabis (TRLV) versus Its Competitors Critical Review

Trulieve Cannabis (NYSE:TRLV) is one of 898 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Trulieve Cannabis to related businesses based on the strength of its dividends, analyst recommendations, valuation, earnings, institutional ownership, profitability and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for Trulieve Cannabis and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1	1	1	0	2.00
Trulieve Cannabis Competitors	7690	13777	25563	1017	2.41

Trulieve Cannabis presently has a consensus price target of $15.00, suggesting a potential upside of 47.78%. As a group, “Pharmaceuticals” companies have a potential upside of 39.87%. Given Trulieve Cannabis’ higher probable upside, equities analysts clearly believe Trulieve Cannabis is more favorable than its competitors.

Earnings & Valuation

This table compares Trulieve Cannabis and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Trulieve Cannabis	$1.18 billion	-$116.38 million	92.27
Trulieve Cannabis Competitors	$3.53 billion	$3.16 billion	550.34

Trulieve Cannabis’ competitors have higher revenue and earnings than Trulieve Cannabis. Trulieve Cannabis is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Trulieve Cannabis and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	-41.55%	-4.24%	-1.72%
Trulieve Cannabis Competitors	-2,378.12%	-221.74%	-16.00%

Insider and Institutional Ownership

32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.8% of Trulieve Cannabis shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Trulieve Cannabis competitors beat Trulieve Cannabis on 7 of the 11 factors compared.

Trulieve Cannabis Company Profile

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.